---
title: "The Epic Growth/Turnaround Story Behind This Overlooked HealthTech Stock Mach7 Tech (ASX:M7T)"
description: "Mach7 Technologies (ASX: M7T) CEO Teri Thomas joins Wei Sim of Homodeus Research to break down the company's turnaround, its vendor-neutral imaging platform, and why the unglamorous world of medical image management is becoming critical AI infrastructure. Teri brings a rare playbook to the role — 20 years at Epic Systems (joining when it had under 100 employees, leaving when it had over 10,000) and a prior CEO stint at ASX-listed Volpara Health Technologies, where she led a turnaround before its acquisition by Lunit. In the past year: costs down 6%, zero debt, positive operating cash flow in Q2 and Q3, and a new modular product platform (Flamingo Architecture) now live with paying customers. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ WHAT WE COVER ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ → What a vendor-neutral archive (VNA) actually is — and why most competitors aren't truly neutral → Why AI in radiology is stalling — and what has to change first → Flamingo Architecture: Mach7's shift from archive vendor to modular imaging platform → How Teri is applying Epic's customer success playbook at Mach7 → Mach7 vs ProMedicus: frenemies sharing 12+ customers → The FDA barrier slowing AI adoption — and how hospitals could route around it → FY27 priorities: pipeline growth, product expansion, financial discipline ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ TIMESTAMPS ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 0:00 Introduction 0:35 What Mach7 does 0:58 3 reasons to watch Mach7 now 1:21 Teri Thomas's background (Epic, Volpara) 2:43 Enterprise imaging market overview 3:44 Tailwinds: radiologist shortage, AI, interoperability 6:32 Product suite: VNA, eUnity, Flamingo 9:06 What is a vendor-neutral archive? 10:51 eUnity: zero-footprint FDA-approved viewer 12:42 Key differentiators & security 14:25 Financial snapshot 15:08 Flamingo Architecture explained 16:08 FY27 go-to-market & sales strategy 20:23 Teri's Epic learnings & leadership style 23:13 Volpara turnaround lessons 25:19 Biggest market opportunities 26:29 Incentive structure & culture code 31:05 Why AI needs the data plumbing solved first 33:48 Mach7 as the AI data foundation 36:27 FDA approvals & the trust problem in radiology 38:21 FY27 strategic priorities 41:36 Mach7 vs ProMedicus 45:11 Closing ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ABOUT ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ Homodeus Research covers high-conviction small and mid-cap opportunities in healthcare technology and beyond. This content is for informational purposes only and does not constitute financial advice. 🔔 Subscribe for more investor interviews and company deep-dives."
canonical_url: "https://homodeus.one/research/videos/YMbk0rYaDTU"
markdown_url: "https://homodeus.one/research/videos/YMbk0rYaDTU.md"
published_date: "2026-07-08T09:25:00+00:00"
modified_date: "2026-08-21T08:45:33.139Z"
thumbnail_url: "https://i2.ytimg.com/vi/YMbk0rYaDTU/hqdefault.jpg"
embed_url: "https://www.youtube.com/embed/YMbk0rYaDTU"
source_url: "https://www.youtube.com/watch?v=YMbk0rYaDTU"
access: "full"
source: "Homodeus Research"
---

# The Epic Growth/Turnaround Story Behind This Overlooked HealthTech Stock Mach7 Tech (ASX:M7T)

Published 2026-07-08T09:25:00+00:00.

Mach7 Technologies (ASX: M7T) CEO Teri Thomas joins Wei Sim of Homodeus Research to break down the company's turnaround, its vendor-neutral imaging platform, and why the unglamorous world of medical image management is becoming critical AI infrastructure.

Teri brings a rare playbook to the role — 20 years at Epic Systems (joining when it had under 100 employees, leaving when it had over 10,000) and a prior CEO stint at ASX-listed Volpara Health Technologies, where she led a turnaround before its acquisition by Lunit.

In the past year: costs down 6%, zero debt, positive operating cash flow in Q2 and Q3, and a new modular product platform (Flamingo Architecture) now live with paying customers.

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
WHAT WE COVER
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
→ What a vendor-neutral archive (VNA) actually is — and why most competitors aren't truly neutral
→ Why AI in radiology is stalling — and what has to change first
→ Flamingo Architecture: Mach7's shift from archive vendor to modular imaging platform
→ How Teri is applying Epic's customer success playbook at Mach7
→ Mach7 vs ProMedicus: frenemies sharing 12+ customers
→ The FDA barrier slowing AI adoption — and how hospitals could route around it
→ FY27 priorities: pipeline growth, product expansion, financial discipline

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
TIMESTAMPS
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
0:00 Introduction
0:35 What Mach7 does
0:58 3 reasons to watch Mach7 now
1:21 Teri Thomas's background (Epic, Volpara)
2:43 Enterprise imaging market overview
3:44 Tailwinds: radiologist shortage, AI, interoperability
6:32 Product suite: VNA, eUnity, Flamingo
9:06 What is a vendor-neutral archive?
10:51 eUnity: zero-footprint FDA-approved viewer
12:42 Key differentiators & security
14:25 Financial snapshot
15:08 Flamingo Architecture explained
16:08 FY27 go-to-market & sales strategy
20:23 Teri's Epic learnings & leadership style
23:13 Volpara turnaround lessons
25:19 Biggest market opportunities
26:29 Incentive structure & culture code
31:05 Why AI needs the data plumbing solved first
33:48 Mach7 as the AI data foundation
36:27 FDA approvals & the trust problem in radiology
38:21 FY27 strategic priorities
41:36 Mach7 vs ProMedicus
45:11 Closing

━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
ABOUT
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Homodeus Research covers high-conviction small and mid-cap opportunities in healthcare technology and beyond. This content is for informational purposes only and does not constitute financial advice.

🔔 Subscribe for more investor interviews and company deep-dives.

Watch: https://www.youtube.com/watch?v=YMbk0rYaDTU